BioSpace News Archive

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces its participation the Oppenheimer 31 st Annual Healthcare Conference.

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2020 .

Seres Therapeutics to Present at the 31 st Annual Oppenheimer Healthcare Conference

Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, March 18, 2021 after the close of financial markets.

Agreement provides exclusive rights to all available data included in the original new drug application for mazindol in the U.S.

InDex Pharmaceuticals Holding AB announced that the list of shareholders on the homepage has been updated with information as of February 26, 2021.

SOC Telemed (SOC) (Nasdaq: TLMD), the largest national provider of acute care telemedicine, today announced that the company will release results for its fourth quarter ended December 31, 2020 on Tuesday, March 30, 2021 after the market closes.

Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the pricing of an underwritten public offering of 28,572,000 shares of its common stock

– Minovia awaiting feedback from FDA on pivotal study design for Pearson Syndrome – – Jacobs to bring extensive clinical development, medical and drug approval experience to Minovia’s leadership team –

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease, today announced that N. Scott Fine, will present at the Inaugural Emerging Growth Virtual Conference presented by M-Vest LLC and Maxim Group LLC